The world needs better vaccines.
We're striving to create them.
CORPORATE OVERVIEW | JUNE 2022
Forward looking statements
Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company's current beliefs and expectations and include, but are not limited to: the company's goal to progress its preclinical and clinical programs, the timing of company milestone achievement, the company's cash balance and the potential of the company's VLP technology. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in the company's business, including, without limitation: the early stage of the company's development efforts; the company's novel and unproven technology and the uncertainties associated with the development of the company's novel candidates and their potential use as part of a pan-respiratory vaccine; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; the company's dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate immunogenicity or efficacy of the company's product candidates that may limit their development, regulatory approval, and/or commercialization as a monovalent vaccine or in a combination or pan-respiratory vaccine; the possibility of disappointing results in later clinical trials despite promising results in earlier preclinical research or clinical trials; the potential for the company's IVX-411 drug product investigation to produce inconclusive results; the potential that, even if the investigation identifies a root cause or contributing factors for the lower than expected interim IVX-411 immunogenicity data, the company may be unable to resolve all ambiguity; the potential that any errors or other unknown factors that may have affected the interim immunogenicity data in the IVX-411-01 clinical trial may have impacted the safety data as well; the potential for the investigation into IVX-411 interim results to impact the results of the company's ongoing trial for IVX-121; competing approaches limiting the commercial value of the company's vaccine candidates and the company's VLP platform technology; regulatory developments in the United States and other countries; the company's ability to obtain and maintain intellectual property protection for its product candidates and maintain its rights under intellectual property licenses; the company's ability to fund its operating plans with its current cash, cash equivalents, and investments; the company's ability to maintain undisrupted business operations during the COVID-19 pandemic, including with respect to clinical trials, manufacturing, and supply chain; and other risks described in the company's prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
2
What if a SINGLE VACCINE could protect you from multiple viral respiratory infections?
AND LAST BEYOND A SINGLE SEASON
AND COVER EMERGING VARIANTS
AND LIMIT UNWANTED SIDE EFFECTS
RSV hMPV
COVID-19 Flu
3
AND significantly reduce hospitalization and death?
U.S. hospitalizations and deaths per year (older adults)
RSV
Annual estimates, older adults 65+
~177,000
hospitalizations
~14,000
deaths
Economic burden:
Estimated at $1.5-3B in direct
medical costs for ages 60+
hMPV
Data support similar
morbidity and
mortality to that seen
with RSV or Flu
COVID-19 | Flu | |
Data set: August 2020-March 2022, | 2019-2020 flu season, older adults 65+ | |
older adults 60+ | ||
~2.5 million | ~171,000 | |
hospitalizations | hospitalizations | |
Total deaths as of March 9, 2022, | ||
Older adults 65+ | ||
~712,000 | ~12,000 | |
deaths | deaths | |
Economic burden: | Economic burden: | |
~$28B in preventable COVID-19 | ~$3.2B in direct medical costs, | |
hospitalizations costs among | adults 65+ drove ~40% of this | |
unvaccinated adults (18+)^ | (~$1.3B) |
^ Extrapolated from six months data to an annualized figure. | |
CDC, RSV Trends and Surveillance; CDC Health Alert network, alert CDCHAN-00443; Sieling et al 2021, Influenza Other Respiratory Viruses; CDC COVID Data Tracker for hospitalizations and deaths; CDC Burden | 4 |
of flu, 2019-2020 flu season; Herring et al 2022, Vaccine; Peterson-KFF Health System Tracker, Unvaccinated COVID-19 hospitalizations cost billions of dollars; Putri et al 2018, Vaccine |
Especially in the MORE VULNERABLE OLDER ADULT POPULATION
WANING IMMUNITY WITH TIME
CREATES RISK FOR INFECTION AND HOSPITALIZATION
R I S K
Maternal | Infant | Older adult |
immunization | immunization | immunization |
PROTECTING THE WORLD'S >600 MILLION* OLDER ADULTS
CAN HELP THEM ACHIEVE THEIR FULL LIFESPAN
*Aged 65+. | |
Adapted from B. Graham, NIH, ResViNet 2017 presentation. | 5 |
NIH News Releases 28 Mar 2016, World's older population grows dramatically |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Icosavax Inc. published this content on 07 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2022 13:11:06 UTC.